Latest & greatest articles for dementia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on dementia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on dementia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for dementia

81. Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease. Full Text available with Trip Pro

Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease. Alzheimer's disease is characterized by amyloid-beta (Aβ) plaques and neurofibrillary tangles. The humanized monoclonal antibody solanezumab was designed to increase the clearance from the brain of soluble Aβ, peptides that may lead to toxic effects in the synapses and precede the deposition of fibrillary amyloid.We conducted a double-blind, placebo-controlled, phase 3 trial involving patients with mild dementia due

2018 NEJM Controlled trial quality: predicted high

82. Advancing Care for Family Caregivers of persons with dementia through caregiver and community partnerships Full Text available with Trip Pro

Advancing Care for Family Caregivers of persons with dementia through caregiver and community partnerships There are currently 15 million Americans who provide over 80% of the care required by their family members with Alzheimer's disease and other dementias. Yet care for caregivers continues to be fragmented and few evidence-based interventions have been translated into routine clinical care and therefore remain inaccessible to most family caregivers. To address this gap, the Caring

2018 Research involvement and engagement

83. Cannabinoids for Behavioural Symptoms in Adults with Dementia: A Review of Clinical Effectiveness and Guidelines

Cannabinoids for Behavioural Symptoms in Adults with Dementia: A Review of Clinical Effectiveness and Guidelines Cannabinoids for Behavioural Symptoms in Adults with Dementia: A Review of Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Cannabinoids for Behavioural Symptoms in Adults with Dementia: A Review of Clinical Effectiveness and Guidelines Cannabinoids for Behavioural Symptoms in Adults with Dementia: A Review of Clinical Effectiveness and Guidelines (...) Published on: January 5, 2018 Project Number: RC0952-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of cannabinoids for the treatment of behavioural symptoms in adults with dementia? What are the evidence-based guidelines regarding the use of cannabinoids for the treatment of behavioural symptoms in adults with dementia? Key Message A total of four publications met the inclusion criteria: two systematic

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

84. Cannabinoids for Behavioural Symptoms in Adults with Dementia: A Review of Clinical Effectiveness and Guidelines

Cannabinoids for Behavioural Symptoms in Adults with Dementia: A Review of Clinical Effectiveness and Guidelines Cannabinoids for Behavioural Symptoms in Adults with Dementia: A Review of Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Cannabinoids for Behavioural Symptoms in Adults with Dementia: A Review of Clinical Effectiveness and Guidelines Cannabinoids for Behavioural Symptoms in Adults with Dementia: A Review of Clinical Effectiveness and Guidelines (...) Published on: January 5, 2018 Project Number: RC0952-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of cannabinoids for the treatment of behavioural symptoms in adults with dementia? What are the evidence-based guidelines regarding the use of cannabinoids for the treatment of behavioural symptoms in adults with dementia? Key Message A total of four publications met the inclusion criteria: two systematic

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

85. Challenges in end-of-life dementia care

Challenges in end-of-life dementia care Challenges in end-of-life dementia care | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword (...) Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Challenges in end-of-life dementia care Article Text Clinical review Challenges in end-of-life dementia care Anne A Fetherston , Grace Rowley , Charlotte L Allan , Statistics from Altmetric.com Footnotes Funding The authors have not declared a specific grant for this research from any funding agency

2018 Evidence-Based Mental Health

86. Risk of suicidal thinking in caregivers of people with dementia should be assessed and monitored by health professionals Full Text available with Trip Pro

Risk of suicidal thinking in caregivers of people with dementia should be assessed and monitored by health professionals Risk of suicidal thinking in caregivers of people with dementia should be assessed and monitored by health professionals | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Risk of suicidal thinking in caregivers of people with dementia should be assessed and monitored by health professionals Article Text Commentary Mental

2018 Evidence-Based Nursing

87. Care of the older person: Antihypertensive medications may reduce the risk of dementia in older African–Americans with hypertension Full Text available with Trip Pro

Care of the older person: Antihypertensive medications may reduce the risk of dementia in older African–Americans with hypertension Antihypertensive medications may reduce the risk of dementia in older African–Americans with hypertension | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Antihypertensive medications may reduce the risk of dementia in older African–Americans with hypertension Article Text Commentary Care of the older person

2018 Evidence-Based Nursing

88. Dementia Villages

Dementia Villages Dementia Villages | CADTH.ca Find the information you need Dementia Villages Dementia Villages Last updated: October 11, 2019 Project Number: EH0071-000 Product Line: Result type: Report Expected Completion Date: October 16, 2019 As the population ages, decision-makers are faced with different choices of care models for people diagnosed with dementia. Recent media reports have focused on dementia villages, first developed at de Hogeweyk in the Netherlands. This Horizon (...) Scanning bulletin will present a narrative review of the literature describing elements of care, as well as evidence and issues concerning dementia villages and similar models or components of care. Stakeholder perspectives and an analysis of policy issues will also be incorporated. Projects listed as “in progress” are at various stages and points of completion. These products have different processes and timelines; therefore, the timing of posting of the final reports varies and expected completion

2018 CADTH - Issues in Emerging Health Technologies

89. Sensory Rooms for Patients with Dementia in Long-Term Care: Clinical and Cost-Effectiveness, and Guidelines

Sensory Rooms for Patients with Dementia in Long-Term Care: Clinical and Cost-Effectiveness, and Guidelines Sensory Rooms for Patients with Dementia in Long-Term Care: Clinical and Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Sensory Rooms for Patients with Dementia in Long-Term Care: Clinical and Cost-Effectiveness, and Guidelines Sensory Rooms for Patients with Dementia in Long-Term Care: Clinical and Cost-Effectiveness, and Guidelines Last updated: July 6, 2018 (...) Project Number: RC0999-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of sensory rooms for patients with dementia in long-term care? What is the cost-effectiveness of sensory rooms for patients with dementia in long-term care? What are the evidence-based guidelines regarding the use of sensory rooms for patients with dementia in long-term care? Key Message Based on the evidence identified

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

90. Does Structured Exercise Improve Cognitive Impairment in People with Mild to Moderate Dementia? A Cost-Effectiveness Analysis from a Confirmatory Randomised Controlled Trial: The Dementia and Physical Activity (DAPA) Trial. Full Text available with Trip Pro

Does Structured Exercise Improve Cognitive Impairment in People with Mild to Moderate Dementia? A Cost-Effectiveness Analysis from a Confirmatory Randomised Controlled Trial: The Dementia and Physical Activity (DAPA) Trial. Previous studies suggest that physical exercise could slow dementia progression. However, evidence for the cost effectiveness of structured exercise is conflicting and based on small trials.The objective of this study was to compare the cost effectiveness of a tailored (...) on the clinical results of the trial, which showed that the structured exercise programme evaluated does not slow cognitive impairment in people with mild to moderate dementia, this economic evaluation shows that the programme is not cost effective.

2018 PharmacoEconomics - open Controlled trial quality: predicted high

91. User experience and clinical effectiveness with two wearable global positioning system devices in home dementia care. Full Text available with Trip Pro

User experience and clinical effectiveness with two wearable global positioning system devices in home dementia care. The user experience and clinical effectiveness with wearable global positioning system (GPS) devices for persons with dementia (PwDs) and caregivers (CGs) remain unclear although many are available.Using a crossover design, 20 dyads tested two similar commercial GPS watches (products A and B) at home for 4 weeks each. Usability, product functions, design features and product

2018 Alzheimer's & dementia (New York, N. Y.) Controlled trial quality: uncertain

92. Antipsychotic medicines for treating agitation, aggression and distress in people living with dementia

Antipsychotic medicines for treating agitation, aggression and distress in people living with dementia Decision aid for Dementia: assessment, management and support for people living with dementia and their carers © NICE 2018. All rights reserved. Subject to Notice of rights. Last updated June 2018 Page 1 of 4 Decision aid Antipsychotic medicines for treating agitation, aggression and distress in people living with dementia Information to help people living with dementia, their family members (...) and carers and their healthcare professionals discuss the options What are the options? People living with dementia can sometimes become aggressive or very agitated. They might also hear voices or see things that are not really there (called hallucinations) or believe that something is real or true when it is not (called delusions). This can be very distressing for them and their carers, and the person may become violent. Several things should be tried first to help calm the person (for example music

2018 Health Information and Quality Authority

93. Enteral (tube) feeding for people living with severe dementia

Enteral (tube) feeding for people living with severe dementia Decision aid for Dementia: assessment, management and support for people living with dementia and their carers © NICE 2018. All rights reserved. Subject to Notice of rights. Last updated June 2018 Page 1 of 2 Decision aid Enteral (tube) feeding for people living with severe dementia Information to help people living with severe dementia, their family members and carers and their healthcare professionals discuss the options What (...) are the options? People living with severe dementia often develop problems with eating and drinking. They may have swallowing problems. If this happens food or saliva may go down their windpipe and cause an infection in their lungs (aspiration pneumonia). This can be serious or even fatal. They may also have a reduced appetite, and in their final weeks or days they may stop eating or drinking altogether. Enteral (tube) feeding usually involves either passing a tube through a person’s nose and down

2018 Health Information and Quality Authority

94. Cohort study: People who face the bereavement of a partner with dementia have poorer mental health than those whose partners are dying from other diseases

Cohort study: People who face the bereavement of a partner with dementia have poorer mental health than those whose partners are dying from other diseases People who face the bereavement of a partner with dementia have poorer mental health than those whose partners are dying from other diseases | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how (...) we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here People who face the bereavement of a partner with dementia have poorer mental health than those

2018 Evidence-Based Nursing

95. Frontotemporal dementia

Frontotemporal dementia Frontotemporal dementia - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Frontotemporal dementia Last reviewed: February 2019 Last updated: August 2018 Summary Manifests primarily as disruption in personality and social conduct, or as a primary language disorder. Almost 50% of all affected people display parkinsonism; a smaller subset may have motor neuron disease. Clinical diagnosis derives (...) primarily from examination and brain imaging. Diagnostic confirmation is based on pathological examination or identification of gene mutation. Treatment is supportive, combining medications with carer guidance, community services, and social work interventions. Definition Frontotemporal dementias (FTDs) are the second most frequent primary neurodegenerative brain diseases (after Alzheimer’s disease) in adults <65 years of age. The FTD spectrum comprises a heterogeneous group of conditions that appear

2018 BMJ Best Practice

96. Assessment of dementia

Assessment of dementia Assessment of dementia - Differential diagnosis of symptoms | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Assessment of dementia Last reviewed: February 2019 Last updated: September 2018 Summary Dementia is a syndrome characterised by an appreciable deterioration in cognition resulting in behavioural problems and impairment in the activities of daily living. Decline in cognition is extensive, often affecting multiple domains (...) of intellectual functioning. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed., (DSM-5). Washington, DC: American Psychiatric Publishing; 2013. Cummings JL, Benson DF. Dementia: a clinical approach. 2nd ed. Boston: Butterworth-Heinemann; 1992. The prevalence of dementia is approximately 1% at the age of 60 years, and doubles every 5 years, to reach 30% to 50% by the age of 85 years. The majority of cases of dementia have degenerative and vascular causes. Thal LJ

2018 BMJ Best Practice

97. Vascular dementia

Vascular dementia Vascular dementia - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Vascular dementia Last reviewed: February 2019 Last updated: August 2018 Summary Chronic progressive multifaceted impairment of cognitive function; a form of dementia. Loss of brain parenchyma is predominately from cerebrovascular causes such as infarction and small-vessel changes. The second most common cause of dementia in older (...) people. A large overlap exists with Alzheimer's dementia and many patients have a mixed form of dementia. Treatment is of limited benefit; early aggressive treatment of vascular risk factors is suggested. Definition Vascular dementia is a chronic progressive disease of the brain bringing about cognitive impairment. The executive functions of the brain such as planning are more prominently affected than memory. Motor and mood changes are often seen early. The underlying damage occurs to both grey

2018 BMJ Best Practice

98. Dementia with Lewy bodies

Dementia with Lewy bodies Dementia with Lewy bodies - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Dementia with Lewy bodies Last reviewed: February 2019 Last updated: August 2018 Summary A neurodegenerative disorder with parkinsonism, progressive cognitive decline, prominent executive dysfunction, and visuospatial impairment. Core clinical features include: recurrent visual hallucinations; cognitive fluctuations (...) )-type pathology. Meta-analyses support the use of cholinesterase inhibitors for the cognitive and the neurobehavioural symptoms. Memantine may be of some value in the treatment of dementia and behavioural symptoms. The use of antipsychotic medication must be minimised due to the increased sensitivity to these medicines' adverse effects, including increased mortality. Levodopa/carbidopa can be used for the motor symptoms, though adverse effects may be restrictive and response limited; clonazepam

2018 BMJ Best Practice

99. Alzheimer's dementia

Alzheimer's dementia Alzheimer's dementia - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Alzheimer's dementia Last reviewed: February 2019 Last updated: September 2018 Summary Chronic, progressive neurodegenerative disorder characterised by a global, non-reversible impairment in cerebral functioning. Characterised by memory loss, loss of social and occupational functioning, diminished executive function, speech (...) support groups are beneficial to caregivers and should be considered, where available. Definition Alzheimer's disease (AD) is a chronic neurodegenerative disease with an insidious onset and progressive but slow decline. AD is the most common type of dementia. Grossman H, Bergmann C, Parker S. Dementia: a brief review. Mt Sinai J Med. 2006 Nov;73(7):985-92. http://www.ncbi.nlm.nih.gov/pubmed/17195884?tool=bestpractice.com Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population

2018 BMJ Best Practice

100. Specialist dementia care units

Specialist dementia care units Specialist dementia care units An Evidence Check rapid review brokered by the Sax Institute for the Commonwealth Department of Health. September 2017 An Evidence Check rapid review brokered by the Sax Institute for the Commonwealth Department of Health. September 2017. This report was prepared by: Malcolm Masso, Cathy Duncan, Pam Grootemaat, Lyn Phillipson, Peter Samsa, Dave Fildes and Rob Gordon. Australian Health Services Research Institute, University (...) www.saxinstitute.org.au knowledge.exchange@saxinstitute.org.au Phone: +61 2 91889500 Suggested Citation: Masso M, Duncan C, Grootematt P, Phillipson L, Samsa P, Fildes D, Gordon R. Specialist dementia care units: an Evidence Check rapid review brokered by the Sax Institute (www.saxinstitute.org.au) for the Commonwealth Department of Health, 2017. Disclaimer: This Evidence Check Review was produced using the Evidence Check methodology in response to specific questions from the commissioning agency

2018 Sax Institute Evidence Check